568 related articles for article (PubMed ID: 21900593)
1. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.
Yonesaka K; Zejnullahu K; Okamoto I; Satoh T; Cappuzzo F; Souglakos J; Ercan D; Rogers A; Roncalli M; Takeda M; Fujisaka Y; Philips J; Shimizu T; Maenishi O; Cho Y; Sun J; Destro A; Taira K; Takeda K; Okabe T; Swanson J; Itoh H; Takada M; Lifshits E; Okuno K; Engelman JA; Shivdasani RA; Nishio K; Fukuoka M; Varella-Garcia M; Nakagawa K; Jänne PA
Sci Transl Med; 2011 Sep; 3(99):99ra86. PubMed ID: 21900593
[TBL] [Abstract][Full Text] [Related]
2. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
3. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects.
Jackson JG; St Clair P; Sliwkowski MX; Brattain MG
Cancer Res; 2004 Apr; 64(7):2601-9. PubMed ID: 15059917
[TBL] [Abstract][Full Text] [Related]
4. Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab.
Iida M; Brand TM; Starr MM; Li C; Huppert EJ; Luthar N; Pedersen MW; Horak ID; Kragh M; Wheeler DL
Neoplasia; 2013 Oct; 15(10):1196-206. PubMed ID: 24204198
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
6. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.
Takezawa K; Pirazzoli V; Arcila ME; Nebhan CA; Song X; de Stanchina E; Ohashi K; Janjigian YY; Spitzler PJ; Melnick MA; Riely GJ; Kris MG; Miller VA; Ladanyi M; Politi K; Pao W
Cancer Discov; 2012 Oct; 2(10):922-33. PubMed ID: 22956644
[TBL] [Abstract][Full Text] [Related]
7. Combining trastuzumab and cetuximab combats trastuzumab-resistant gastric cancer by effective inhibition of EGFR/ErbB2 heterodimerization and signaling.
Zheng L; Tan W; Zhang J; Yuan D; Yang J; Liu H
Cancer Immunol Immunother; 2014 Jun; 63(6):581-6. PubMed ID: 24668364
[TBL] [Abstract][Full Text] [Related]
8. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
9. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.
Schoeberl B; Faber AC; Li D; Liang MC; Crosby K; Onsum M; Burenkova O; Pace E; Walton Z; Nie L; Fulgham A; Song Y; Nielsen UB; Engelman JA; Wong KK
Cancer Res; 2010 Mar; 70(6):2485-94. PubMed ID: 20215504
[TBL] [Abstract][Full Text] [Related]
10. Chronic morphine treatment attenuates cell growth of human BT474 breast cancer cells by rearrangement of the ErbB signalling network.
Weingaertner IR; Koutnik S; Ammer H
PLoS One; 2013; 8(1):e53510. PubMed ID: 23308242
[TBL] [Abstract][Full Text] [Related]
11. Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance.
Quesnelle KM; Grandis JR
Clin Cancer Res; 2011 Sep; 17(18):5935-44. PubMed ID: 21791633
[TBL] [Abstract][Full Text] [Related]
12. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.
Brand TM; Dunn EF; Iida M; Myers RA; Kostopoulos KT; Li C; Peet CR; Wheeler DL
Cancer Biol Ther; 2011 Sep; 12(5):436-46. PubMed ID: 21725209
[TBL] [Abstract][Full Text] [Related]
13. Targeting ERBB receptors shifts their partners and triggers persistent ERK signaling through a novel ERBB/EFNB1 complex.
Vermeer PD; Colbert PL; Wieking BG; Vermeer DW; Lee JH
Cancer Res; 2013 Sep; 73(18):5787-97. PubMed ID: 23811940
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
15. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.
Misale S; Yaeger R; Hobor S; Scala E; Janakiraman M; Liska D; Valtorta E; Schiavo R; Buscarino M; Siravegna G; Bencardino K; Cercek A; Chen CT; Veronese S; Zanon C; Sartore-Bianchi A; Gambacorta M; Gallicchio M; Vakiani E; Boscaro V; Medico E; Weiser M; Siena S; Di Nicolantonio F; Solit D; Bardelli A
Nature; 2012 Jun; 486(7404):532-6. PubMed ID: 22722830
[TBL] [Abstract][Full Text] [Related]
16. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.
Knowlden JM; Hutcheson IR; Jones HE; Madden T; Gee JM; Harper ME; Barrow D; Wakeling AE; Nicholson RI
Endocrinology; 2003 Mar; 144(3):1032-44. PubMed ID: 12586780
[TBL] [Abstract][Full Text] [Related]
17. Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression.
Spangler JB; Manzari MT; Rosalia EK; Chen TF; Wittrup KD
J Mol Biol; 2012 Sep; 422(4):532-44. PubMed ID: 22706026
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members.
Wheeler DL; Huang S; Kruser TJ; Nechrebecki MM; Armstrong EA; Benavente S; Gondi V; Hsu KT; Harari PM
Oncogene; 2008 Jun; 27(28):3944-56. PubMed ID: 18297114
[TBL] [Abstract][Full Text] [Related]
19. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.
Regales L; Gong Y; Shen R; de Stanchina E; Vivanco I; Goel A; Koutcher JA; Spassova M; Ouerfelli O; Mellinghoff IK; Zakowski MF; Politi KA; Pao W
J Clin Invest; 2009 Oct; 119(10):3000-10. PubMed ID: 19759520
[TBL] [Abstract][Full Text] [Related]
20. The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells.
Kawakami H; Okamoto I; Yonesaka K; Okamoto K; Shibata K; Shinkai Y; Sakamoto H; Kitano M; Tamura T; Nishio K; Nakagawa K
Oncotarget; 2014 Dec; 5(23):11847-56. PubMed ID: 25474137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
